Jones Soda buys UCAN assets as its ambitions move beyond soft drinks
The acquisition adds sports-nutrition products to a business whose recent growth has come alongside higher marketing spending and continuing cash demands.
How this story was made
This story was written with AI assistance from PR Newswire’s wire release. Its figures and quotations were checked against their sources, and Digitalage Desk reviewed and approved it before publication. It is published under the name of Peter Michaels, Editor.
Not investment advice.
Jones Soda is expanding from craft beverages into sports nutrition, buying substantially all operating assets of UCAN through its Jones Labs business. The company announced the acquisition on November 16, four days after the transaction closed.
The purchase involved approximately $700,000 in cash and $500,000 in assumed liabilities. UCAN brings energy gels, nutrition bars, drink mixes, hydration products and protein offerings marketed to athletes and active consumers. Jones plans to integrate the brand into its existing operations and distribution channels.
The expansion follows a sharp improvement in the buyer’s own sales. In results released November 10, Jones reported third-quarter revenue of $13.7 million, compared with $4.5 million a year earlier, alongside growth in club-store and direct-to-consumer activity. Net income from continuing operations reached $471,000, reversing a $1.4 million loss.
Gross margin also widened, rising to 34.4% from 28.9%. Selling and marketing expenses increased to $2.3 million from $1 million, although they absorbed a smaller proportion of revenue.
UCAN creates a different operational task from launching another soda flavor. Jones will need to retain the acquired business’s customers while fitting its products into a broader sales operation. That is the practical test behind the company’s expectation of growth from the purchase.
Primary sourcePR Newswire: “Jones Soda Co. Announces Completed Acquisition of UCAN Functional Nutrition Brand Assets Through Jones Labs”The deal brings a near-term obligation: about $400,000 of the assumed liabilities are licensing fees due in January 2027. Jones says approximately $200,000 of that obligation will be settled with common shares issued to Glycologic Limited at the market price when issued. Integrating UCAN and meeting those obligations are the next steps after closing.
End of story


